MENU
+Compare
CLYM
Stock ticker: NASDAQ
AS OF
Jun 6 closing price
Price
$1.39
Change
+$0.15 (+12.10%)
Capitalization
93.93M

CLYM Climb Bio Inc Forecast, Technical & Fundamental Analysis

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases... Show more

CLYM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for CLYM with price predictions
May 28, 2025

CLYM in upward trend: price rose above 50-day moving average on May 28, 2025

CLYM moved above its 50-day moving average on May 28, 2025 date and that indicates a change from a downward trend to an upward trend. In of 47 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 56 cases where CLYM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CLYM just turned positive on May 28, 2025. Looking at past instances where CLYM's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where CLYM advanced for three days, in of 180 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on May 23, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on CLYM as a result. In of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLYM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CLYM entered a downward trend on May 27, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.486) is normal, around the industry mean (16.080). P/E Ratio (0.000) is within average values for comparable stocks, (59.383). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.197). Dividend Yield (0.000) settles around the average of (0.039) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (268.270).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CLYM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLYM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
CLYM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

CLYM is expected to report earnings to fall 51.61% to -15 cents per share on August 19

Climb Bio Inc CLYM Stock Earnings Reports
Q2'25
Est.
$-0.15
Q1'25
Missed
by $0.16
The last earnings report on May 14 showed earnings per share of -31 cents, missing the estimate of -15 cents. With 1.01M shares outstanding, the current market capitalization sits at 93.93M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL200.420.21
+0.10%
Apple
SPY587.73-3.42
-0.58%
SPDR® S&P 500® ETF
BTC.X107802.330000-1192.312500
-1.09%
Bitcoin cryptocurrency
TSLA356.90-5.99
-1.65%
Tesla
GME31.21-3.80
-10.85%
GameStop Corp

CLYM and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CLYM has been loosely correlated with ABOS. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if CLYM jumps, then ABOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLYM
1D Price
Change %
CLYM100%
+6.84%
ABOS - CLYM
40%
Loosely correlated
N/A
ATOS - CLYM
34%
Loosely correlated
-3.13%
LRMR - CLYM
34%
Loosely correlated
+8.74%
ADIL - CLYM
34%
Loosely correlated
+1.49%
PDSB - CLYM
33%
Loosely correlated
-4.20%
More